CagriSema
Amylin + GLP-1 Dual Agonist
Best For
Clients seeking maximum weight loss support through complementary receptor pathways
~25%
Body weight reduction in REDEFINE trials
2
Complementary satiety pathways engaged
Phase 3
Clinical development stage (REDEFINE program)
How It Works
CagriSema combines an amylin analogue (cagrilintide) acting on the area postrema to promote satiety with a GLP-1 agonist (semaglutide) for incretin-mediated appetite suppression and metabolic improvement. These dual pathways produce additive weight loss beyond either agent alone. Phase 3 trials in the REDEFINE program demonstrate approximately 25% total body weight reduction.
Key Research Areas
Dual Pathway Activation
Engages both amylin and GLP-1 signaling for complementary appetite control
Superior Weight Loss
Phase 3 data shows ~25% body weight reduction — exceeding single-agent results
Metabolic Improvement
Semaglutide component enhances insulin sensitivity and glucose regulation
Satiety Enhancement
Cagrilintide targets brainstem satiety centers independent of incretin pathways
Research Highlights
- First combination to pair amylin and GLP-1 agonism in a single protocol
- Additive weight loss beyond what either pathway achieves alone
Featured Research
Formulation Notes
Common concentrations referenced in published clinical studies:
[CS10]10mg (Cagri 5mg + Sema 5mg)Category
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides ...
Explore Lean Body category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Related Compounds
Semaglutide
GLP-1 Receptor Agonist
- Most-studied GLP-1 agonist with over 10,000 participants across STEP trials
- Demonstrated cardiovascular benefit independent of weight loss
Reference Codes
[SM5]5mg[SM10]10mg[SM15]15mg[SM20]20mg[SM30]30mgCagrilintide
Long-Acting Amylin Analogue
- Amylin-pathway satiety — complementary to GLP-1 receptor agonists
- Long-acting acylated design supports convenient once-weekly dosing
Reference Codes
[CGL5]5mg[CGL10]10mgTirzepatide
Dual GIP/GLP-1 Agonist
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Reference Codes
[TR20]20mg[TR40]40mgEvidence reviewed: March 2026